Literature DB >> 27928967

Hot Topics in Dry Eye Disease.

Pablo Alberto Chiaradia1, Luis Alberto Zeman Bardeci2, Sebastian Dankert2, Marcos Omar Mendaro2, Andrzej Grzybowski3.   

Abstract

BACKGROUND: Dry eye disease (DED) is a multifactorial disease of the tears and ocular surface that results in symptoms such as discomfort, visual disturbance, and tear film instability, with potential damage to the ocular surface. The principal pathological mechanisms of DED are hyperosmolarity and inflammation. These mechanisms are deeply interrelated and lead to a self-perpetuating "vicious circle".
METHODS: The objective of this review is to describe novel pharmacological and non-pharmacological treatments for DED.
RESULTS: Based on the better understanding of the physiopathology of the disease, new treatment strategies have been developed.
CONCLUSION: The focus of the management of DED has been taken away from just reducing symptoms and redirected towards specific targets of its physiopathology, being inflammation the most addressed topic. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Dry eye disease; anti-inflammatory agents; biologic agents; device development; drug development; molecular targeted treatments; physiopathology; treatment

Mesh:

Substances:

Year:  2017        PMID: 27928967     DOI: 10.2174/1381612822666161208094841

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

Review 1.  Evidence that Dry Eye Represents a Chronic Overlapping Pain Condition.

Authors:  Alexandra E Levitt; Anat Galor; Aneesa R Chowdhury; Elizabeth R Felix; Constantinos D Sarantopoulos; Gerald Y Zhuang; Dennis Patin; William Maixner; Shad B Smith; Eden R Martin; Roy C Levitt
Journal:  Mol Pain       Date:  2017 Jan-Dec       Impact factor: 3.395

2.  Air pollutant particulate matter 2.5 induces dry eye syndrome in mice.

Authors:  Gang Tan; Juan Li; Qichen Yang; Anhua Wu; Dong-Yi Qu; Yahong Wang; Lei Ye; Jing Bao; Yi Shao
Journal:  Sci Rep       Date:  2018-12-13       Impact factor: 4.379

3.  A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.

Authors:  Mike Taylor; George Ousler; Gail Torkildsen; Claire Walshe; Matthew C T Fyfe; Adele Rowley; Steve Webber; John D Sheppard; Ajay Duggal
Journal:  Clin Ophthalmol       Date:  2019-02-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.